In a world where biotech startups burn millions on glossy websites and buzzwords, Alzohis is a ghost ship. With a digital footprint of zero and a $1.4M revenue stream, this 9-person team is playing a completely different game. They aren't chasing VC hype; they're building something real in the lab while the rest of the industry chases traffic.

"Zero web traffic isn't a failure—it's a signal that the real work is happening offline, where patents matter more than pageviews."

The absence of structured data, social profiles, or even a basic landing page is telling. Most biotech startups over-engineer their digital presence to signal legitimacy to investors. Alzohis does the opposite. This silence is strategic—it protects IP, avoids premature scrutiny, and forces potential partners to engage directly rather than through a marketing funnel. In biotech, obscurity can be a competitive advantage.

• Revenue-first model: $1.4M from 9 people suggests high-margin IP or strategic deals
• Digital blackout: Zero web presence protects IP and filters for serious partners only
• Capital efficiency: No public funding rounds means they're either bootstrapped or privately funded
• Stealth mode: Operating below the radar while competitors burn cash on visibility